Canada’s Federal Court of Appeal Limits Damages Available to Delayed Generics

June 08, 2009

Tags:

Food and Drug Regulatory Intellectual Property Intellectual Property Litigation Patents Pharmaceuticals

Related Expertise

Related Insights

Indirect comparisons to an innovative drug’s data can trigger data protection provisions
COVID-19 triggers Canadian intellectual property deadline extensions until August 24, 2020
Video: what does a new ruling on Canada’s equivalent to patent term extension mean for the pharmaceutical industry?
Health Canada instructed to reconsider scope of CSP protection for drug containing multiple active ingredients
Video: how will the Federal Court’s ruling on changes to the Patented Medicines Regulations impact the pharmaceutical industry?

Back